Format

Send to

Choose Destination
See comment in PubMed Commons below
Adv Drug Deliv Rev. 2003 Feb 10;55(2):171-97.

Bispecific antibody conjugates in therapeutics.

Author information

  • 1Abbott Laboratories, Dept. 04A6, Bldg. AP8B, 100 Abbott Park Road, Abbott Park, IL 60064, USA. ying.cao@add.ssw.abbott.com

Abstract

Bispecific monoclonal antibodies have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-arm structure of bsMAb allows researchers to place a therapeutic agent on one arm while allowing the other to specifically target the disease site. The therapeutic agent can be a drug, toxin, enzyme, DNA, radionuclide, etc. Furthermore, bsMAb may redirect the cytotoxicity of immune effector cells towards the diseased cells or induce a systemic immune response against the target. BsMAb holds great promise for numerous therapeutic needs in the light of: (1) recent breakthroughs in recombinant DNA technology, (2) the increased number of identified disease targets as the result of the completion of human genomic map project, and (3) a better understanding of the mechanism of human immune system. This review focuses on therapeutic applications and production of bsMAb while providing the up-to-date clinical trial information.

PMID:
12564976
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center